Eton Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Eton Pharmaceuticals

11/05/2023 22:03

* Eton Pharmaceuticals Inc  ETON.OQ  reported a quarterly
adjusted
loss of 10 cents​​ per share for the quarter ended in March. The
lone analyst forecast for the quarter was for a loss of 14 cents
per share.
    * Revenue rose 143.8% to $5.30 million from a year ago;
analysts
expected $4.56 million. 
    * Eton Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 10 cents​.
    * The mean earnings estimate of analysts had fallen by
about 16.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Eton Pharmaceuticals Inc shares had fallen by 8.8% this
quarter and gained 24.5% so far this year.
    * The company reported a quarterly loss of $2.66 million.
    * Wall Street's median 12-month price target for Eton
Pharmaceuticals Inc is $10.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
11 at 09:02 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.14          -0.10          Beat
 Dec. 31 2022      0.01           0.04           Beat
 Sep. 30 2022      -0.15          -0.12          Beat
 Jun. 30 2022      0.03           -0.06          Missed